María Reig

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

María Reig, Zoe Mariñó, Christie Perelló et al. · Journal of Hepatology · 2016 · 1K citations · Full text

Medicine, Infectious Diseases, Oncology +10

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Hepatology · 2016 · 692 citations · Full text

Medicine, Oncology, Pharmacotherapy +5

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design

Marta Burrel, María Reig, Alejandro Forner et al. · Journal of Hepatology · 2012 · 481 citations · Full text

Medicine, Oncology, Pharmacology +15

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma

Alejandro Forner, Carmen Ayuso, Marı́a Varela et al. · Cancer · 2008 · 425 citations · Full text

Medicine, Oncology, Radiology +17

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11